Pinealon / PE22-28 / Selank Peptide Screening Form Template

Pinealon, PE22-28, and Selank are neuropeptides with complementary anxiolytic, cognitive-enhancing, and sleep-regulatory effects. Pinealon supports pineal gland function and neuroprotection; PE22-28 is a synthetic peptide with antidepressant and cognitive-enhancement properties; Selank is an anxiolytic peptide that modulates GABAergic and serotonergic activity. This combination screening form helps providers evaluate patients with anxiety, cognitive concerns, and sleep disturbances while documenting neuropsychiatric contraindications.

4 sections
17 fields
HIPAA-ready
3 citations

Free Template

Pinealon / PE22-28 / Selank Peptide Screening Form

Preview Form Automate This Form
No account required to use template
Customize with your practice branding
Reviewed against HIPAA & DEA guidelines

Form Preview

This is how the form appears to patients. Customize with your practice name and branding.

Your Practice Name

Pinealon / PE22-28 / Selank Peptide Screening Form

Preview
1

General Patient Information

Please provide your personal information.

First Name

Jane

Last Name

Smith

Date of Birth

Can you confirm you are 18 years or older?

Height

e.g. 5'8"

Weight

e.g. 170 lbs

2

Medical History

Please answer all questions as accurately as possible. Your provider will review this information.

Are you actively taking any medications? If so, please list them.

List all current medications, dosages, and frequencies

Do you have any medication allergies? If so, please list them.

List all known drug allergies and reactions

Are you currently being treated or have you been treated for any medical conditions? If so, please list them.

List all current and past medical conditions

Have you had any past surgeries? If so, please list them.

List all surgeries and approximate dates

What is/was your sex assigned at birth?

Male

Emergency contact name and phone number

Name — (555) 000-0000

Mailing address

123 Main St, City, State, ZIP

Any other questions or concerns?

Optional — share anything else you'd like your provider to know

3

Symptoms

Select all symptoms that currently apply to you.

Which of the following symptoms are you experiencing?
4

Medical Conditions

Select all conditions that currently apply to you.

Do any of the following apply to you?

Preview only. Your live form will include your branding and e-signature capture.

Submit

Compliance & Regulatory Notes

Review these notes before deploying this form in your practice.

All three peptides are prescribed off-label. Informed consent should list each compound individually. See FSMB: https://www.fsmb.org

Patients on psychiatric medications (antidepressants, anxiolytics, antipsychotics) require careful evaluation for drug interactions before initiating neuropeptide therapy.

These peptides must be dispensed by a licensed compounding pharmacy. See FDA: https://www.fda.gov/drugs/human-drug-compounding

Want This Form Automated?

Karpa Health turns static intake forms into a fully automated clinical workflow. Branded, HIPAA-compliant, and connected to compounding pharmacies.

  • Branded intake on your website
  • AI contraindication screening
  • One-click prescribing to pharmacies
  • Automated refill management
  • E-signatures and HIPAA audit trail
  • 50-state provider network included
Book a Demo

Free 30-minute walkthrough

Sources & References

  1. FDA Human Drug Compounding Guidance
  2. FSMB Off-Label Prescribing Guidelines
  3. NIH - Selank Neuropeptide Research

Frequently Asked Questions

How does Selank differ from traditional anti-anxiety medications?

Selank is a synthetic heptapeptide analogue of tuftsin with anxiolytic properties that does not cause sedation, dependence, or withdrawal effects associated with benzodiazepines. It modulates GABAergic and serotonergic systems through a distinct mechanism.

Can these peptides be used alongside psychiatric medications?

Concurrent use with antidepressants, anxiolytics, or other CNS-active medications requires careful provider evaluation. Potential additive effects and drug interactions must be reviewed on a case-by-case basis.